for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Teva Pharmaceutical Industries Ltd (ADR)

TEVA.N

Latest Trade

10.34USD

Change

0.14(+1.37%)

Volume

4,952,791

Today's Range

10.04

 - 

10.43

52 Week Range

6.07

 - 

22.34

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Teva Pharmaceutical Industries Ltd - Appointment Of Eli Kalif As Executive Vice President And Chief Financial Officer

Nov 7 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA ANNOUNCES APPOINTMENT OF NEW CHIEF FINANCIAL OFFICER.TEVA PHARMACEUTICAL INDUSTRIES LTD - APPOINTMENT OF ELI KALIF AS EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER.TEVA PHARMACEUTICAL INDUSTRIES LTD - KALIF WILL BEGIN HIS EMPLOYMENT ON DECEMBER 22, 2019.TEVA PHARMACEUTICAL INDUSTRIES LTD - KALIF MOST RECENTLY AS SENIOR VICE PRESIDENT, FINANCE AT FLEX LTD.

Teva Pharmaceutical Industries Q3 Non-GAAP Earnings Per Share $0.58

Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $0.58.Q3 GAAP LOSS PER SHARE $0.29.Q3 REVENUE $4.3 BILLION.FULL YEAR 2019 BUSINESS OUTLOOK REVISED.SEENET REVENUES OF $17.2 - $ 17.4 BILLION.SEES 2019 EPS OF $2.30 - $2.50 (PRIOR OUTLOOK $2.20 - $2.50).GENERIC PRODUCTS REVENUES IN OUR NORTH AMERICA SEGMENT IN Q3 OF 2019 WERE $914 MILLION FLAT COMPARED TO Q3 OF 2018.SEES FY FREE CASH FLOW OF $1.7 BILLION - $2.0 BILLION VERSUS PRIOR FORECAST $1.6 - $2.0 BILLION.COPAXONE REVENUES IN OUR NORTH AMERICA SEGMENT IN Q3 OF 2019 DECREASED BY 41% TO $271 MILLION, COMPARED TO Q3 OF 2018.TEVA PHARMA - AS OF SEPTEMBER 30, 2019, THE PORTION OF TOTAL DEBT CLASSIFIED AS “SHORT-TERM” WAS 12%, SIMILAR TO SUCH PORTION AS OF JUNE 30, 2019.TEVA PHARMA - AS OF SEPTEMBER 30, 2019, OUR DEBT WAS $26,942 MILLION, COMPARED TO $28,726 MILLION AS OF JUNE 30, 2019.TEVA - ON TRACK TO ACHIEVE TWO-YEAR RESTRUCTURING TARGET OF A $3 BILLION SPEND BASE REDUCTION.TEVA PHARMA - DECREASE IN DEBT AS OF SEPT. 30 WAS MAINLY DUE TO REPAYMENT AT MATURITY OF $1,556 MILLION 1.7% SENIOR NOTES AND EXCHANGE RATE FLUCTUATIONS.ON TRACK TO ACHIEVE TWO-YEAR RESTRUCTURING TARGET OF A $3 BILLION SPEND BASE REDUCTION.

Co-Lead Attorneys For Plaintiff Municipalities Not On Board With Teva Framework For Agreement In Principle - CNBC

Oct 21 (Reuters) - :CO-LEAD ATTORNEYS FOR THE PLAINTIFF MUNICIPALITIES SAY THEY ARE NOT ON BOARD WITH TEVA FRAMEWORK FOR AGREEMENT IN PRINCIPLE - CNBC.

Teva Settles Track 1 Opioid Cases & Reaches Agreement To Settle Remaining Litigation

Oct 21 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA SETTLES TRACK 1 OPIOID CASES AND REACHES AGREEMENT ON FRAMEWORK TO SETTLE REMAINING LITIGATION.SETTLEMENT RESOLVES COUNTIES' CLAIMS AND REMOVES TEVA FROM TRACK 1 OPIOID LITIGATION.UNDER TERMS OF SETTLEMENT, TO PROVIDE 2 COUNTIES WITH SUBOXONE VALUED AT $25 MILLION AND DISTRIBUTED OVER 3 YEARS.TO DONATE BUPRENORPHINE NALOXONE, IN QUANTITIES OF UPTO AMOUNT NEEDED TO MEET MAJORITY OF U.S. PATIENT NEED OVER NEXT 10 YRS, OF ABOUT $23 BILLION.WOULD ALSO PROVIDE A CASH PAYMENT OF UP TO $250 MILLION OVER 10 YEARS.CONFIRMS AGREEMENT WITH GROUP OF ATTORNEYS GENERAL FROM NORTH CAROLINA, PENNSYLVANIA, TENNESSEE, TEXAS, FOR GLOBAL SETTLEMENT FRAMEWORK.ANNOUNCED SETTLEMENT AGREEMENT WITH CUYAHOGA AND SUMMIT COUNTIES OF OHIO.UNDER SETTLEMENT, WILL PROVIDE CASH PAYMENT OF $20 MILLION, PAID OVER 3 YEARS.

Teva, Mckesson, Cardinal Health, Amerisourcebergen reach opioid settlement for $260 mln - plaintiff lawyer

Oct 21 (Reuters) - McKesson Corp <MCK.N>::TEVA PHARMACEUTICAL INDUSTRIES, MCKESSON CORP, CARDINAL HEALTH, AMERISOURCEBERGEN REACH OPIOID SETTLEMENT FOR $260 MILLION - PLAINTIFF LAWYER.

Ohio Counties, Drug Firms Reach $260 mln Settlement In Opioid Epidemic Case - Wapo

Oct 21 (Reuters) - :OHIO COUNTIES, DRUG FIRMS REACH $260 MILLION SETTLEMENT IN OPIOID EPIDEMIC CASE, AVERTING TRIAL - WAPO.

Foamix Announces Settlement Of Litigation With Teva Relating To Finacea Foam

Oct 21 (Reuters) - Foamix Pharmaceuticals Ltd <FOMX.O>::FOAMIX ANNOUNCES SETTLEMENT OF LITIGATION WITH TEVA RELATING TO FINACEA FOAM.‍FOAMIX PHARMACEUTICALS - CO, WITH LEO PHARMA, ENTERED SETTLEMENT WITH TEVA AFFILIATE TO RESOLVE PENDING PATENT LITIGATION INVOLVING FINACEA FOAM​.‍FOAMIX PHARMACEUTICALS - DETAILS OF SETTLEMENT AGREEMENT ARE CONFIDENTIAL, AND SETTLEMENT AGREEMENT IS SUBJECT TO REVIEW OF FTC AND U.S. DOJ.

BRIEF- FOUR DRUG COMPANIES REACH LAST-MINUTE SETTLEMENT IN OPIOID LITIGATION - WSJ

Removes extraneous words:.

UK's MHRA Says Teva UK Recalling Some Batches Of Ranitidine

Oct 17 (Reuters) - UK's MHRA::UK'S MHRA - ISSUED ALERT TO HEALTHCARE PROFESSIONALS, AS TEVA UK LTD IS RECALLING ALL UNEXPIRED STOCK OF CERTAIN BATCHES OF 2 TYPES OF RANITIDINE.UK'S MHRA - 2 PRODUCTS AFFECTED BY TEVA UK RECALL ARE RANITIDINE EFFERVESCENT TABLETS 150 MICROGRAMS AND 300 MICROGRAMS.UK'S MHRA - TEVA UK RECALL IS PRECAUTIONARY MEASURE DUE TO POSSIBLE CONTAMINATION OF ACTIVE SUBSTANCE IN ZANTAC, RANITIDINE WITH IMPURITY CALLED NDMA.UK'S MHRA - ON TEVA UK LTD'S RANITIDINE RECALL, ALL REMAINING STOCK SHOULD BE QUARANTINED AND RETURNED WITHOUT DELAY TO THE SUPPLIER.UK'S MHRA - HEALTHCARE PROFESSIONALS HAVE BEEN TOLD TO STOP SUPPLYING THE TWO RANITIDINE PRODUCTS IMMEDIATELY.

U.S. Drug Companies Pursuing $50 Bln Settlement Of Opioid Cases- NYT

Oct 16 (Reuters) - :U.S. DRUG COMPANIES PURSUING $50 BILLION SETTLEMENT OF OPIOID CASES - NYT.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up